To limit off-target effects, we did not modify cells genetically but instead we have chosen patient-derived melanoma populations with originally distinct molecular characteristics: (i) BRAFWT, MITF-Mhigh/NF-κBlow, (ii) BRAFV600E, MITF-Mhigh/NF-κBhigh, (iii) BRAFV600E, MITF-Mlow/NF-κBhigh. This evidence concerns the gene MITF and melanoma.